AC
ADPT icon

Aristeia Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Aristeia Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.94M Buy
+183,500
New +$2.81M 0.05% 210

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aristeia Capital's ADPT Position: Q2 2026 in Review

Aristeia Capital opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 183,500 shares worth $3.94M. The stake represents 0.05% of the portfolio and ranks #210 among its holdings.

300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Aristeia Capital held 183,500 shares of Adaptive Biotechnologies worth $3.94M as of Q2 2026.
  • Adaptive Biotechnologies was a new Aristeia Capital position in Q2 2026.
  • Adaptive Biotechnologies made up 0.05% of Aristeia Capital's portfolio in Q2 2026, its #210 holding.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.